| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Friday’s Close |
|---|---|---|---|---|---|
| NVS | Novartis AG | $86.16 | $201.86B | Uptrend |
Venture Capital Deals Of The Week: SoftBank Hands WeWork $1B
https://seekingalpha.com/article/4198000-venture-capital-deals-week-softbank-hands-wework-1b?source=feed
Aug 11, 2018 - Welcome to Seeking Alpha’s Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings. Did we miss a notable deal? Let us
0
Country Trust Bank Buys Incyte Corp, First Trust Preferred Securities and Income ETF, Visa Inc, ...
http://www.gurufocus.com/news/721728/country-trust-bank-buys-incyte-corp-first-trust-preferred-securities-and-income-etf-visa-inc-sells-bristolmyers-squibb-company-monsanto-co-cardinal-health-inc
Aug 10, 2018 - Country Trust Bank Buys Incyte Corp, First Trust Preferred Securities and Income ETF, Visa Inc, Sells Bristol-Myers Squibb Company, Monsanto Co, Cardinal Health Inc, Stocks: V,XLY,NVS,BIIB,AWK,EW,INCY,FPE,JEC,BND,LOW,MUSA,MO, release date:Aug 10, 2018
0
Vaccinex Readies $45 Million U.S. IPO
https://seekingalpha.com/article/4190170-vaccinex-readies-45-million-u-s-ipo?source=feed_sector_healthcare
Jul 25, 2018 - Vaccinex has filed proposed terms for a $45 million IPO of its common stock. The firm is developing potential treatments for Huntington's Disease and non-small cell lung cancer based on its VX15 candi
0
It's Not All About the Dividend
http://www.gurufocus.com/news/712444/its-not-all-about-the-dividend
Jul 25, 2018 - It's Not All About the Dividend, Stocks: JNJ,PFE,KMB,PG,VZ,T,NVS,CL,EL,MDLZ,KHC,, release date:Jul 25, 2018
0
Dividend Sensei's Portfolio Update 44: 5 Important Charts All Investors Need To See
https://seekingalpha.com/article/4189432-dividend-senseis-portfolio-update-44-5-important-charts-investors-need-see?source=feed_all_articles
Jul 24, 2018 - Investing is always done with some important goal in mind.To achieve our financial dreams we need to adopt sound and time tested investing strategies.Five important charts help to hammer home the impo
0
Lilly (LLY) Tops Q2 Earnings, Chooses IPO Path for Elanco
http://www.zacks.com/stock/news/313012/lilly-lly-tops-q2-earnings-chooses-ipo-path-for-elanco?cid=CS-ZC-FT-313012
Jul 24, 2018 - Eli Lilly (LLY) tops estimates for both earnings and sales in the second quarter and raises guidance for 2018. It will divest its Elanco unit into a new public company. Stock up in pre-market trading.
0
Pharma/Biotech Stock Q2 Earnings on Jul 25: GILD, VRTX & GSK
http://www.zacks.com/stock/news/312876/pharma-biotech-stock-q2-earnings-on-jul-25-gild-vrtx-gsk?cid=CS-ZC-FT-312876
Jul 24, 2018 - The going has been good for the pharma giants, which reported second-quarter results so far. Let us see what is in store for biotech bigwig GILD, VRTX and large-cap pharma company GSK.
0
Materialise NV announces pricing of 3M ADS
https://seekingalpha.com/news/3372626-materialise-nv-announces-pricing-3m-ads?source=feed_news_all
Jul 23, 2018 - Materialise NV (NASDAQ:MTLS) priced public offering of 3M ADS at $13/ADS.Underwriters have a 30-day option to purchase up to an additional 0.45M ADSs at the public offering price, less the underwriti
0
What's in the Cards for Glaxo (GSK) This Earnings Season?
http://www.zacks.com/stock/news/312807/whats-in-the-cards-for-glaxo-gsk-this-earnings-season?cid=CS-ZC-FT-312807
Jul 23, 2018 - Glaxo's (GSK) Pharmaceuticals and Vaccines segments are likely to boost sales in Q2 earnings.
0
Biotech Stocks Are Tariff-Safe And Building Momentum
https://seekingalpha.com/article/4189138-biotech-stocks-tariff-safe-building-momentum?source=feed_all_articles
Jul 23, 2018 - The Nasdaq Biotechnology Index is poised to make a 52-week high and most likely an all-time high shortly thereafter. Biotech stocks are more insulated from the biggest concern for the market - the tar
0
Page 1>
Related Companies
| Name | Exchange | Price | Mkt Cap | |
| PFE | Pfizer, Inc. | NYSE | $35.96 | $213.87B |
| MRK | Merck & Company, Inc. | NYSE | $65.13 | $177.63B |
| ABBV | AbbVie Inc. | NYSE | $87.48 | $139.45B |
| SNY | Sanofi | NYSE | $50.34 | $126.04B |
| NVO | Novo Nordisk A/S | NYSE | $49.22 | $125.51B |